MedTrace Logo

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

NCT06416735 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-16

No results posted yet for this study

Summary

The study is a non-pharmacological interventional, single-center, national, non-randomised, comparative and open label.

Conditions

  • Hypertension Essential
  • Salt Excess
  • Genetic Hypertension

Interventions

DRUG

Amiloride

administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours

Sponsors & Collaborators

  • Ospedale San Raffaele

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2020-07-20
Completion
2020-07-20
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06416735 on ClinicalTrials.gov